Expression of MAS1 in breast cancer

Cancer Science

Volumn 106, Issue 9, 2015, Pages 1240-1248

  Luo, Yi ^a   Tanabe, Eriko ^a   Kitayoshi, Misaho ^a   Nishiguchi, Yukiko ^a   Fujiwara, Rina ^a   Matsushima, Sayako ^a   Sasaki, Takamitsu ^b   Sasahira, Tomonori ^a   Chihara, Yoshitomo ^a   Nakae, Dai ^c   Fujii, Kiyomu ^a   Ohmori, Hitoshi ^a   Kuniyasu, Hiroki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOKYO UNIVERSITY OF AGRICULTURE   (Japan)

Author keywords

ACE2; Angiotensin; Angiotensin1 7; Breast cancer; MAS1

Indexed keywords

ANGIOTENSIN[1-7]; ANTINEOPLASTIC AGENT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LOSARTAN; MAS1 PROTEIN; PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; XANTHENONE; G PROTEIN COUPLED RECEPTOR; ONCOPROTEIN; PROTO-ONCOGENE PROTEINS C-MAS-1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUMINAL A BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; CARCINOMA, DUCTAL, BREAST; GENETICS; PATHOLOGY; PROCEDURES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MCF-7 CELLS; MICE; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84942193794     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12719     Document Type: Article

References (35)

1. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385-99.
2. Kuniyasu H. Multiple roles of angiotensin in colorectal cancer. World J Clin Oncol 2012; 3: 150-4.
3. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-36.
4. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 203-99.
5. Shimomoto T, Ohmori H, Luo Y et al. Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer. Clin Exp Metastasis 2012; 29: 915-25.
6. Luo Y, Ohmori H, Shimomoto T et al. Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells. Pathobiology 2011; 78: 285-90.
7. Zhou L, Luo Y, Sato S et al. Role of two types of angiotensin II receptors in colorectal carcinoma progression. Pathobiology 2014; 81: 169-75.
8. Campbell DJ. Vasopeptidase inhibition: A double-edged sword? Hypertension 2003; 41: 383-9.
9. Regulska K, Stanisz B, Regulski M. The renin-angiotensin system as a target of novel anticancer therapy. Curr Pharm Des 2013; 19: 7103-25.
10. Johansson A, Helou K, Levan G. Cytogenetic localization of cancer-related genes in the rat and comparative mapping studies in human and mouse. Cytogenet Cell Genet 1998; 81: 217-21.
11. Bernardi S, Zennaro C, Palmisano S et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. J Renin Angiotensin Aldosterone Syst 2012; 13: 202-9.
12. Wakao F, Nishimoto H, Katanoda K, Tsukuma H, Mikami H, eds. Cancer Statistics in Japan, 2013, 2013 edn. Tokyo: National Cancer Center, 2013.
13. Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011; 18: 165-73.
14. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. Breast 2010; 19: 312-21.
15. Bagaria SP, Ray PS, Sim MS et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg 2014; 149: 125-9.
16. Brady-West DC, McGrowder DA. Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev 2011; 12: 2139-43.
17. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137: 183-92.
18. Chekhun S, Bezdenezhnykh N, Shvets J, Lukianova N. Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. Exp Oncol 2013; 35: 174-9.
19. Kuniyasu H, Luo Y, Fujii K et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver. Gut 2010; 59: 348-56.
20. Kuniyasu H, Oue N, Wakikawa A et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-70.
21. Chihara Y, Fujimoto K, Kondo H et al. Anti-tumor effects of liposome-encapsulated titanium dioxide in nude mice. Pathobiology 2007; 74: 353-8.
22. Kuniyasu H, Oue N, Sasahira T et al. Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 2009; 42: 110-21.
23. Hernandez Prada JA, Ferreira AJ, Katovich MJ et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension 2008; 51: 1312-7.
24. Kuniyasu H. The molecular pathology of gastric cancer. In: Kuriyama S, Yoshiji H, eds. New Perspectives in Cancer Research and Therapy 2005. Kerala: Research Signpost, 2005; 85-98.
25. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138-40.
26. Petrelli F, Coinu A, Borgonovo K et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014; 144: 223-32.
27. Castro CH, Santos RA, Ferreira AJ, Bader M, Alenina N, Almeida AP. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005; 46: 937-42.
28. Arumugam S, Thandavarayan RA, Palaniyandi SS et al. Candesartan cilexetil protects from cardiac myosin induced cardiotoxicity via reduction of endoplasmic reticulum stress and apoptosis in rats: involvement of ACE2-Ang (1-7)-mas axis. Toxicology 2012; 291: 139-45.
29. Karimi B, Hafidzi MN, Panandam JM, Fuzina NH. Comparison of effect of sex hormone manipulation during neonatal period, on mRNA expression of Slc9a4, Nr3c2, Htr5b and Mas1 in hippocampus and frontal cortex of male and female rats. J Biol Regul Homeost Agents 2013; 27: 869-74.
30. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kappaB-dependent pathways. Br J Pharmacol 2012; 166: 1964-76.
31. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007; 50: 1093-8.
32. Rao C, Shetty J, Prasad KH. Immunohistochemical profile and morphology in triple-negative breast cancers. J Clin Diagn Res 2013; 7: 1361-5.
33. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181-9.
34. Kagara N, Huynh KT, Kuo C et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol 2012; 181: 257-67.
35. Whitelaw NC, Chong S, Morgan DK et al. Reduced levels of two modifiers of epigenetic gene silencing, Dnmt3a and Trim28, cause increased phenotypic noise. Genome Biol 2010; 11: R111.